CTRI/2023/11/059909尚未招募4 期
Hydroxychloroquine in neoadjuvant treatment of triple negative breast cancer - NI
Dr Ananth Pai0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients diagnosed with triple negative breast cancer and receiving neoadjuvant chemotherapy (NACT).
- •Age more than 18yrs
- •Performance Status less than or equal to 2
排除标准
- •Metastatic triple negative breast cancer.
- •Patients taking alternative therapies concurrently.
- •Receipt of hydroxychloroquine (HCQ) within the past 6 months.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQ
研究者
相似试验
已完成
4 期
Hydroxychloroquine real world efficacy assessment as add on therapy compare to gliptin in IndiaCTRI/2018/06/014382Patna Medical College2,000
尚未招募
3 期
Effect of hydroxychloroquine therapy in new-onset type 1 diabetesCTRI/2022/08/044961Post Graduate Institute of Medical Education and Research PGIMER Chandigarh
已完成
3 期
study of hydroxychloroquine in comparison with pioglitazone in patients with type II diabetes mellitusCTRI/2009/091/001036Ipca Laboratories Limited267
进行中（未招募）
不适用
Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - NDHIV infection (immunological nonresponders).MedDRA version: 9.1Level: LLTClassification code 10008922EUCTR2009-012499-28-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)40
招募中
2 期
COVID-19 prophylaxis with hydroxychloroquine in Front-line Health and Allied-Health Care Workers: The COVID-SHIELD TrialCOVID-19 infectionInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000501943Walter and Eliza Hall Institute of Medical Research650